Rhumbline Advisers Corcept Therapeutics Inc Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Corcept Therapeutics Inc stock. As of the latest transaction made, Rhumbline Advisers holds 202,832 shares of CORT stock, worth $10.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
202,832
Previous 202,788 0.02%
Holding current value
$10.1 Million
Previous $6.59 Million 42.43%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$29.51 - $46.26 $1,298 - $2,035
44 Added 0.02%
202,832 $9.38 Million
Q2 2024

Aug 01, 2024
SELL
$22.21 - $34.48 $87,862 - $136,402
-3,956 Reduced 1.91%
202,788 $6.59 Million
Q1 2024

May 09, 2024
SELL
$21.1 - $27.46 $117,083 - $152,375
-5,549 Reduced 2.61%
206,744 $5.21 Million
Q4 2023

Feb 08, 2024
BUY
$24.82 - $32.88 $174,608 - $231,310
7,035 Added 3.43%
212,293 $6.9 Million
Q3 2023

Nov 09, 2023
BUY
$21.97 - $33.8 $9,974 - $15,345
454 Added 0.22%
205,258 $5.59 Million
Q2 2023

Aug 08, 2023
SELL
$21.44 - $25.15 $128,211 - $150,397
-5,980 Reduced 2.84%
204,804 $4.56 Million
Q1 2023

May 11, 2023
BUY
$19.2 - $24.47 $249,139 - $317,522
12,976 Added 6.56%
210,784 $4.57 Million
Q4 2022

Feb 14, 2023
BUY
$19.95 - $29.96 $21,027 - $31,577
1,054 Added 0.54%
197,808 $4.02 Million
Q3 2022

Nov 10, 2022
BUY
$24.7 - $29.12 $244,060 - $287,734
9,881 Added 5.29%
196,754 $5.05 Million
Q2 2022

Aug 11, 2022
BUY
$17.33 - $25.3 $93,876 - $137,050
5,417 Added 2.99%
186,873 $4.44 Million
Q1 2022

May 12, 2022
BUY
$16.53 - $25.21 $47,854 - $72,982
2,895 Added 1.62%
181,456 $4.09 Million
Q4 2021

Feb 10, 2022
SELL
$17.1 - $23.34 $18,194 - $24,833
-1,064 Reduced 0.59%
178,561 $3.54 Million
Q3 2021

Nov 12, 2021
SELL
$19.68 - $22.53 $786,944 - $900,907
-39,987 Reduced 18.21%
179,625 $3.54 Million
Q2 2021

Aug 05, 2021
SELL
$19.97 - $24.43 $76,525 - $93,615
-3,832 Reduced 1.71%
219,612 $4.83 Million
Q1 2021

May 06, 2021
BUY
$23.49 - $30.56 $129,993 - $169,119
5,534 Added 2.54%
223,444 $5.32 Million
Q4 2020

Feb 10, 2021
BUY
$16.78 - $27.3 $1,057 - $1,719
63 Added 0.03%
217,910 $5.7 Million
Q3 2020

Nov 12, 2020
SELL
$12.46 - $19.98 $278,917 - $447,252
-22,385 Reduced 9.32%
217,847 $3.79 Million
Q2 2020

Aug 13, 2020
SELL
$11.0 - $18.26 $152,801 - $253,649
-13,891 Reduced 5.47%
240,232 $4.04 Million
Q1 2020

May 06, 2020
BUY
$10.11 - $14.04 $21,231 - $29,484
2,100 Added 0.83%
254,123 $3.02 Million
Q4 2019

Feb 05, 2020
BUY
$12.06 - $16.96 $232,034 - $326,310
19,240 Added 8.27%
252,023 $3.05 Million
Q3 2019

Oct 23, 2019
BUY
$10.41 - $14.66 $1,863 - $2,624
179 Added 0.08%
232,783 $3.29 Million
Q2 2019

Aug 14, 2019
BUY
$9.78 - $12.76 $43,188 - $56,348
4,416 Added 1.94%
232,604 $2.59 Million
Q1 2019

May 01, 2019
SELL
$10.03 - $15.71 $27,863 - $43,642
-2,778 Reduced 1.2%
228,188 $2.68 Million
Q4 2018

Jan 31, 2019
BUY
$11.29 - $17.19 $529,997 - $806,967
46,944 Added 25.51%
230,966 $3.09 Million
Q3 2018

Nov 07, 2018
BUY
$12.27 - $15.65 $9,509 - $12,128
775 Added 0.42%
184,022 $2.58 Million
Q2 2018

Aug 06, 2018
BUY
$15.3 - $19.69 $180,387 - $232,145
11,790 Added 6.88%
183,247 $2.88 Million
Q1 2018

May 02, 2018
BUY
$14.59 - $25.5 $49,606 - $86,700
3,400 Added 2.02%
171,457 $2.82 Million
Q4 2017

Feb 09, 2018
BUY
$15.77 - $20.72 $1.24 Million - $1.63 Million
78,700 Added 88.07%
168,057 $3.04 Million
Q3 2017

Nov 06, 2017
BUY
$12.3 - $19.3 $1.1 Million - $1.72 Million
89,357
89,357 $1.73 Million

Others Institutions Holding CORT

# of Institutions
347
Shares Held
86.1M
Call Options Held
1.12M
Put Options Held
667K
View Full List

About CORCEPT THERAPEUTICS INC

CORT Quotes by TradingView
  • Ticker CORT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,105,000
  • Market Cap $5.34B
  • Description
  • Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...
More about CORT
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email